Scinai Expands CDMO Platform with Recipharm Israel Acquisition, Reports Mixed Q1 2026 Results
Event summary
- Scinai completed the acquisition of Recipharm Israel, adding a second manufacturing site in Yavne and expanding its CDMO platform.
- Q1 2026 revenues were $489K, down from $586K in Q1 2025, with $200K contributed by the newly acquired Yavne facility.
- Net income of $3.6M was reported, driven by a $6.2M non-cash bargain purchase gain from the Recipharm Israel acquisition.
- Scinai prioritized the development of a systemic IL-17 bispecific antibody as the lead validation program for its NanoAb platform.
- The company advanced multiple non-dilutive funding initiatives, with several grant decisions expected in the second half of 2026.
The big picture
Scinai's acquisition of Recipharm Israel marks a strategic shift towards expanding its CDMO business while maintaining its focus on therapeutic development. The move aligns with broader industry trends of vertical integration in biopharmaceutical manufacturing, aiming to create a more resilient operating model. The company's emphasis on non-dilutive funding reflects a capital-efficient approach to growth, though the success of this strategy will depend on securing grant approvals and maintaining operational efficiency.
What we're watching
- Integration Challenges
- How Scinai will integrate the Recipharm Israel acquisition and optimize the expanded CDMO platform.
- Grant Funding Success
- Whether Scinai can secure multiple non-dilutive funding opportunities to support future growth.
- Therapeutic Development
- The pace at which Scinai advances its PC111 and NanoAb programs, particularly the systemic IL-17 bispecific antibody.
Related topics